Skip to main content
. 2023 Apr 3;11:1147566. doi: 10.3389/fped.2023.1147566

Table 3.

Codes describing the disadvantages of the UAR and strategies for improvement.

Disadvantages of the UAR Strategies to improve the UAR
  • • 

    Co-medications Not Apparent [C81]

  • • 

    In utero Exposure Not Apparent [C83]

  • • 

    Metabolites Not Apparent [C86]

  • • 

    Multiple Administrations to Mother Not Apparent [C87]

  • • 

    Prematurity Not Apparent [C93]

  • • 

    Separate by Specific Cases and Scenarios [C108]

  • • 

    Potential to Appear Subjective or Misinterpreted [C92]

  • • 

    Explain More About How the Model was Made (Inputs and Assessments) [C97]

  • • 

    Explain More About UAR Advantages [C98]

  • • 

    Difficult to Understand or Too Complex [C82]

  • • 

    Provide Guidance to Interpret the UAR [C106]

  • • 

    Make Visual Representation Essential [C102]

  • • 

    User Friendly for Non-pharmacists [C100]

  • • 

    User Friendly for Pharmacists [C101]

  • • 

    Provide a Definitive Bottom Line [C104]

  • • 

    Lack of Maternal Perspective [C84]

  • • 

    Provide a Greater Maternal Emphasis [C105]

  • • 

    Limited Information on Adverse Effects (Exposure-Response Relationship) [C85]

  • • 

    Provide Prospective Predictive Evidence [C107]

  • • 

    Not Enough for Clinical Decision-making [C88]

  • • 

    Combine the UAR with Another Resource [C96]

  • • 

    Unusable in Current Form (Too Novel) [C94]

  • • 

    Add a Summary Statement [C95]

  • • 

    Give Specific Training [C99]

  • • 

    Overcome Simulation Skepticism [C103]